Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma

Abstract

BACKGROUND The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional FUDR with biologic response modifiers (BRMs) has not been evaluated extensively in patients with metastatic RCC. METHODS Thirty‐nine previously untreated patients with metastatic RCC were treated with infusional FUDR at 0.075 mg/kg/day for 14 days of a 28‐day cycle. Beginning with the second cycle of FUDR, 24 patients received subcutaneous interferon‐α‐2b (3 million U 3 times a week for Weeks 1 and 2) and 15 received subcutaneous interleukin‐2 (IL‐2) (5 million U/m2 5 days a week for 3 weeks, followed by 1 week off). The dose of FUDR was increased by 0.025 mg/kg each cycle until the maximum tolerated dose for each patient was reached. RESULTS Five patients receiving FUDR plus interferon achieved a partial response and 1 achieved a complete response whereas 3 patients receiving FUDR plus IL‐2 achieved a partial response, for an overall response rate of 23%. The median survival for all patients was 21 months, and 8 patients still were alive 6–57+ months after the initiation of therapy. Toxicity was mild to moderate, and was comprised primarily of fatigue, diarrhea, dacryocystitis, and fluid retention (in the IL‐2 cohort). CONCLUSIONS FUDR in conjunction with IL‐2 or interferon appears to produce response rates comparable to those observed with other programs utilizing BRMs and generally is well tolerated. FUDR regimens may be useful in the treatment of metastatic RCC in the outpatient community setting. Cancer 2000;88:1310–6. © 2000 American Cancer Society.

Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision

“…5‐Fluorouracil has also been used concurrently with these treatments . Chemotherapeutic treatment results for cutaneous metastases of RCC are unsatisfactory, with maximal partial response rates of 5–20% reported …”

Ocular Metastasis as First Presentation of Renal Cell Carcinoma: Report of 2 Cases

“…The most frequent metastatic sites are lung (76%), regional lymph nodes (66%), bone (42%), and liver (41%). 9 Ocular metastases from renal cell carcinoma have been reported as uncommon, 3 even though the actual incidence is not known.…”

Metástasis lingual de carcinoma renal

“…Como pauta de tratamiento de la enfermedad metastásica se utiliza interleuquina-2 o interferon alfa; el porcentaje de respuestas parciales ronda el 5-20%, con un porcentaje de pacientes con respuesta completa menor del 5%. 7 El pronóstico del carcinoma renal con metástasis es pobre. O`Dea y cols.…”

“…The percentage of partial response is around 5-20%, and the percentage of patients with complete response is less than 5%. 7 The prognosis for renal carcinoma with metastasis is poor. O'Dea et al reported a survival rate at two years of 78% when metastasis to the oral cavity is identified, and a survival at 5 years of 50% when metastasis develops after a nephrectomy.…”